{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:55:57Z","timestamp":1747184157483,"version":"3.40.5"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["20 1226 PjF"],"award-info":[{"award-number":["20 1226 PjF"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blood pressure measurements form a critical component of adverse event monitoring for tyrosine kinase inhibitors, but might also serve as a biomarker for dose titrations. This study explored the impact of various sources of within\u2010individual variation on blood pressure readings to improve measurement practices and evaluated the utility for individual\u2010 and population\u2010level dose selection. A pharmacokinetic\u2013pharmacodynamic modeling framework was created to describe circadian blood pressure changes, inter\u2010 and intra\u2010day variability, changes from dipper to non\u2010dipper profiles, and the relationship between drug exposure and blood pressure changes over time. The framework was used to quantitatively evaluate the influence of physiological and pharmacological aspects on blood pressure measurements, as well as to compare measurement techniques, including office\u2010based, home\u2010based, and ambulatory 24\u2010h blood pressure readings. Circadian changes, as well as random intra\u2010day and inter\u2010day variability, were found to be the largest sources of within\u2010individual variation in blood pressure. Office\u2010based and ambulatory 24\u2010h measurements gave rise to potential bias (&gt;5\u2009mmHg), which was mitigated by model\u2010based estimations. Our findings suggest that 5\u20138 consecutive, home\u2010based, measurements taken at a consistent time around noon, or alternatively within a limited time frame (e.g., 8.00 a.m. to 12.00 p.m. or 12.00 p.m. to 5.00 p.m.), will give rise to the most consistent blood pressure estimates. Blood pressure measurements likely do not represent a sufficiently accurate method for individual\u2010level dose selection, but may be valuable for population\u2010level dose identification. A user\u2010friendly tool has been made available to allow for interactive blood pressure simulations and estimations for the investigated scenarios.<\/jats:p>","DOI":"10.1111\/cts.13423","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T17:58:55Z","timestamp":1664042335000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine\u2010kinase inhibitors"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-9813","authenticated-orcid":false,"given":"Maddalena","family":"Centanni","sequence":"first","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel","family":"Thijs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC Location VU University  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Desar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.787"},{"key":"e_1_2_10_3_1","unstructured":"MRC Protein Phosphorylation Unit. List of clinically approved kinase inhibitors.2021. Accessed April 22 2022.https:\/\/www.ppu.mrc.ac.uk\/list\u2010clinically\u2010approved\u2010kinase\u2010inhibitors"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0455"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3362-1"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1184649"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2016.1148601"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","unstructured":"YuH SteeghsN NijenhuisCM.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Am J Hypertens2014;305\u201325.","DOI":"10.1007\/s40262-014-0137-2"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.61"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.62"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2806"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12193"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.08.012"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv103"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2273"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0887"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00316"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70464-9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.73"},{"key":"e_1_2_10_20_1","unstructured":"CentanniM KrishnanSM FribergLE.A pharmacometric framework for dose individualisation of sunitinib in GIST [abstract]. Popul Approach gr Eur 27;2018. Accessed August 10 2022. 2018 29 May\u20131 June. Montreux. page Abstract nr 8741.https:\/\/www.page\u2010meeting.org\/pdf_assets\/6339\u2010PAGE2018_MCENTANNI.pdf."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0030"},{"volume-title":"Pressure Monitoring in Cardiovascular Medicine and Therapeutics","year":"2001","author":"Blood WWB","key":"e_1_2_10_22_1"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.149690"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S164903"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-319-07410-8_4","volume-title":"White Coat Hypertension: An Unresolved Diagnostic and Therapeutic Problem","author":"Parati G","year":"2015"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.08.021"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13119"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/590626"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpt088"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2019.27.1.24"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.106907"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90053-4"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01320.x"},{"key":"e_1_2_10_34_1","first-page":"1043","article-title":"A cyclic fluctuation model for 24\u2010h ambulatory blood pressure monitoring in Chinese patients with mild to moderate hypertension","volume":"34","author":"Sheng Y","year":"2013","journal-title":"Acta Pharmacol"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0207-5"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.20"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12587"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12206"},{"key":"e_1_2_10_39_1","unstructured":"DehezM ChenelM JochemsenR RagotS.Population modeling approach of circadian blood pressure variations using ambulatory monitoring in dippers and non dippers;2006. Accessed August 10 2022.https:\/\/www.page\u2010meeting.org\/?abstract=989."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12644"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-98141-3"},{"key":"e_1_2_10_42_1","unstructured":"McPhersonJ ChangWC ChengJ AllaireJJ XieY.shiny: Web Application Framework for R.2017. Accessed August 10 2022.https:\/\/shiny.rstudio.com\/."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.4196\/kjpp.2012.16.2.97"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.189011"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.63"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/IBPC.S49205"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2010.194"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5224-6"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12196"},{"issue":"1","key":"e_1_2_10_50_1","first-page":"S87","article-title":"Developmental pharmacodynamics and modeling in pediatric drug development","volume":"59","author":"Conklin LS","year":"2019","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T16:07:02Z","timestamp":1692461222000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/cts.13423"],"URL":"https:\/\/doi.org\/10.1111\/cts.13423","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"type":"print","value":"1752-8054"},{"type":"electronic","value":"1752-8062"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"2022-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}